Methodology

PROMETHEUS TPMT Genetics helps classify patients as 1 of 3 genotypes: homozygous normal (wild type), heterozygous or homozygous recessive. Because each patient metabolizes thiopurines differently, the efficacy and toxicity of thiopurines can vary widely from patient to patient. Knowledge of the TPMT genotype may reduce time to response, allow physicians to individualize dosing, identify patients in whom thiopurine therapy should be avoided and help reduce the risk of leukopenia.

A qualitative evaluation, to determine a patient’s genetic ability to produce the thiopurine methyltransferase (TPMT) enzyme.